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effects of thyroid hormones on energy balanceMayte Alvarez-Crespo 1,2, Robert I. Csikasz 3, Noelia Martínez-Sánchez 1,2, Carlos Diéguez 1,2,
Barbara Cannon 3, Jan Nedergaard 3,*, Miguel López 1,2,**ABSTRACT
Objective: Classically, metabolic effects of thyroid hormones (THs) have been considered to be peripherally mediated, i.e. different tissues in the
body respond directly to thyroid hormones with an increased metabolism. An alternative view is that the metabolic effects are centrally regulated.
We have examined here the degree to which prolonged, centrally infused triiodothyronine (T3) could in itself induce total body metabolic effects
and the degree to which brown adipose tissue (BAT) thermogenesis was essential for such effects, by examining uncoupling protein 1 (UCP1) KO
mice.
Methods: Wildtype and UPC1 KO mice were centrally-treated with T3 by using minipumps. Metabolic measurements were analyzed by indirect
calorimetry and expression analysis by RT-PCR or western blot. BAT morphology and histology were studied by immunohistochemistry.
Results: We found that central T3-treatment led to reduced levels of hypothalamic AMP-activated protein kinase (AMPK) and elevated body
temperature (0.7 C). UCP1 was essential for the T3-induced increased rate of energy expenditure, which was only observable at thermoneutrality
and notably only during the active phase, for the increased body weight loss, for the increased hypothalamic levels of neuropeptide Y (NPY) and
agouti-related peptide (AgRP) and for the increased food intake induced by central T3-treatment. Prolonged central T3-treatment also led to
recruitment of BAT and britening/beiging (“browning”) of inguinal white adipose tissue (iWAT).
Conclusions: We conclude that UCP1 is essential for mediation of the central effects of thyroid hormones on energy balance, and we suggest
that similar UCP1-dependent effects may underlie central energy balance effects of other agents.
 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Thyroid hormones (THs) 3,30,5,50 tetraiodothyronine (T4) and 3,30,5-
triiodothyronine (T3) control important biological processes, including
metabolism and energy balance [1e3]. Hyperthyroidism is associated
with an increase in metabolic rate. There are basically two models for
how thyroid hormones induce this hypermetabolism. According to the
classical view, the effect is (mainly) peripheral, i.e. thyroid hormones
affect peripheral tissues directly and increase their metabolism
through mechanisms not presently fully understood. In contrast, ac-
cording to a novel view, the effect is (mainly) central, in that thyroid
hormones may affect centers in the brain that stimulate the meta-
bolism of certain peripheral organs via the (sympathetic) nervous
system (SNS) [4e6]. Indeed, both types of thyroid hormone action may
occur.
An organ that is likely to be responsible for an increase in metabolism
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www.molecularmetabolism.comprotein 1 (UCP1) in the mitochondria of BAT, the tissue has a special
ability and high efficiency for converting food or stored energy (body
fat) into heat [7]. The possibility of central effects of thyroid hormones
in the regulation of BAT thermogenesis was proposed a long time ago
[4], but this was mainly based on a central effect of thyroid hormones
on body temperature control and, through this, a secondary effect on
BAT. We later presented evidence for a more specific link between the
central effects of thyroid hormones on BAT [5]. Particularly, central T3
affects cells in the ventromedial nucleus of the hypothalamus (VMH).
This decreases the phosphorylation (and thus the activity) of AMP-
activated protein kinase (AMPK) in the tissue, and this leads to
increased tone in the sympathetic nerves innervating BAT. However, an
actual increase in metabolic rate signaled through this pathway has not
as yet been demonstrated, and it is therefore also unknown to what
extent the stimulation of BAT is responsible for the metabolic ther-
mogenic response and for the other metabolic effects of central T3-
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Original articleinvestigate the role of BAT and UCP1 on the thermogenic effects of
central T3-treatment. We found that the entire thermogenic effect of
central T3-treatment was dependent upon the presence of UCP1.
Additionally, further metabolic effects, such as T3-induced hyper-
phagia, were also entirely UCP1-dependent. The possible significance
of these observations on the understanding of T3 effects in model
animals, as well as in humans, is evident, and this pathway may
additionally be involved in the mediation of broad metabolic effects of
other centrally acting agents.
2. EXPERIMENTAL PROCEDURES
2.1. Animals
Ucp1(/) (UCP1 KO) male mice (8-10 weeks-old; initially generated
by replacing exon 2 and part of exon 3 with a neomycin resistance
gene by homologous recombination [8]) and their corresponding
wildtype (C57BL/6), to which the UCP1 KO mice had been backcrossed
for >10 generations, were obtained from our own breeding of inbred
lines in the Wenner-Gren Institute.
2.2. Experimental layout
The mice were acclimated for one month to 18 C to recruit BAT. They
had ad libitum access to standard chow and tap water and were
exposed to a 12 h light/12 h dark cycle. During the third week at 18 C,
they were separated into single cages. Throughout the actual experi-
ment, the mice were moved to a thermoneutral environment (30 C
with relative humidity of 45e52%) in order to acutely eliminate the
extra-metabolism needed to defend the body temperature at lower
temperatures. Body temperature, body weight and quantity of chow
consumed by each mouse were measured every day at 10.30e11.30
AM (i.e. in the middle of the light phase). The general layout of the
experiment was as follows: on day 0, after measuring body temper-
ature and body weight, the mice underwent surgery to position the
osmotic minipumps delivering vehicle or T3 directly into the brain. For
the anesthesia, we added 1 ml of ketamine and 250 ml of xylazine to
6 ml of saline and the volume injected was 100 ml per 10 g of body
weight. Mice were then moved to 30 C for recovery. On day 1, mice
were kept undisturbed at 30 C. On day 2, the mice were placed in
indirect calorimetry metabolic chambers (the temperature in the
chambers was set to 30 C). On days 3 and 4, calorimetric mea-
surements were performed; mice were taken out of the boxes for a
short period of time each day to measure different parameters. On day
5, mice were removed from the metabolic chambers and placed in a
room at 30 C. On day 6, body composition was measured, and mice
were anesthetized with CO2 and then decapitated. Several tissues
were dissected out. We used 10 animals per experimental group.
Since there is a limitation in the number of metabolic cages, mice were
divided in 5 cohorts each containing 2 animals for each treatment (2
WT/vehicle þ 2 WT/T3 þ 2 KO/vehicle þ 2 KO/T3). One wildtype
mouse from the vehicle-treated group was removed from all compi-
lations because it behaved totally differently from the rest of the mice
in the same group (including this mouse yields a P value of 0.06 for the
T3 effect on the mean metabolic rate). The study was approved by the
Animal Ethics Committee of the Northern Stockholm Region.
2.3. Central T3 administration
Central T3 was administered by osmotic minipumps (micro-osmotic
pump, model 1007D, Alzet; Cupertino, CA, USA) that were placed
subcutaneously in the scapular region of mice. The minipumps were
directly connected to an intracerebroventricular (ICV) cannula targeting
the lateral right ventricle in the brain, as previously described [9e11].272 MOLECULAR METABOLISM 5 (2016) 271e282  2016 The Authors. Published by Elsevier GmbH. TT3 (8 ng/day; Sigma; St Louis, MO, USA) or its vehicle (saline þ 1 mM
NaOH) was continuously delivered during the experiment. The dose of
T3 was selected on the basis of our former studies [5,12], with
consideration of the higher metabolism of mice as compared to rats.
(This dose is infinitely small compared to the doses that are used to
induce T3 effects peripherally and found not to affect circulating levels
of T4 and T3, demonstrating lack of leaking from the cerebrospinal
fluid to the circulation [5,12,13]). Immediately after the surgery, mice
were placed at 30 C.
2.4. Metabolic measurements
Every day (from day 0 to day 6) between 10:30e11:00 AM, mice were
taken out of the chambers (if relevant), and body temperature was
determined with a rectal probe for mice (BAT-12 microprobe ther-
mometer, Physitemp Instruments, Inc; Clifton, NJ, USA). Body weight
and the quantity of food consumed were also measured at this time.
Food was weighed when supplied, and remaining food was subtracted
to calculate the food eaten per day.
2.5. Indirect calorimetry
Indirect calorimetry was analyzed with the INCA System (Somedic;
Hörby, Sweden) [14]. Two days after the placement of the osmotic
minipump, mice in their home cages were placed in a temperature-
controlled (30 C) box through which air was pumped. After calibrat-
ing the system with the reference gases (18% and 25% O2 in N2), the
metabolic rate was measured for 3 nights and the corresponding days.
O2 consumption (VO2) and respiratory quotient (RQ) were recorded
every second minute.
2.6. Tissue dissection
At the end of the treatment (day 6), mice were sedated with CO2 before
decapitation and dissected to collect brain, interscapular brown adi-
pose tissue (iBAT) and inguinal white adipose tissue (iWAT). Tissues
were weighed, quickly frozen in liquid nitrogen and stored at 80 C
until use.
2.7. Western blotting
Mediobasal hypothalamic dissections (removed from the frozen brains)
and iBAT total samples were homogenized in lysis buffer (consisting of
a mix of 5 ml TriseHCl, 0.5 ml 0.2 M EGTA, 0.5 ml 0.2 M EDTA, 1 ml
Triton-X 100, 1 ml 0.1 M sodium orthovanadate, 0.21 g sodium
fluoride, 0.22 g sodium pyrophosphate and 9.2 g of 0.27 M sucrose,
made up with distilled water to 100 ml and adjusted to 7.5 pH) and
freshly added protease inhibitor cocktail tablets (Roche Diagnostics;
Indianapolis, IN, USA). The protein concentration was determined by
the Bradford Method and the total protein content of the tissues was
calculated. The protein lysates were subjected to SDS-PAGE, elec-
trotransferred to polyvinylidene difluoride membranes (PVDF; Millipore;
Billerica, MA, USA) with a semidry blotter and probed with antibodies
against UCP1 and AgRP (Abcam; Cambridge, UK), pAMPKa-Thr172
(Cell Signaling; Danvers; MA, USA), NPY (Santa Cruz Biotechnology;
Dallas, TX, USA), a-tubulin and b-actin (Sigma; St Louis, MO, USA), as
previously described [5,10,11,15e17]. Each membrane was then
incubated with the corresponding secondary antibody: anti-mouse,
anti-rabbit or anti-goat (all of them from DAKO, Glostrup, Denmark).
The membranes were exposed to an X-ray film and developed using
developer (Developer G150, AGFA HealthCare: Mortsel, Belgium) and
Fixator (Manual Fixing G354; AGFA HealthCare; Mortsel, Belgium).
Quantification was performed with the ImageJ 1.33 software (NIH,
Bethesda, MD, USA). Values were expressed relative to b-actin levels
(hypothalamic samples) or a-tubulin (iBAT samples). No significanthis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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changes were found in the protein levels of the loading controls (see
below; Supplemental Figure 3).
2.8. Real-time quantitative PCR
Real-time PCR was performed to analyze UCP1 mRNA levels in iWAT.
Specific sets of primers and probes for UCP1 (TaqMan Gene Expression
Assays, Ref Mm00494070_m1; Life Technologies; Carlsbad, CA, US)
were used, as previously described [5,10]. All reactions were carried out
using the following cycling parameters: 50 C for 2min, 95 C for 10min
followed by 40 cycles of 95 C for 15 s, 60 C for 1 min. Values were
expressed relative to HPRT (hypoxanthine-guanine phosphoribosyl-
transferase) levels (Probe: FAM-50- CGACCCTCAGTCCCAGCGTCGT-
GAT-30-TAMRA, Fw Primer: 50-AGCCGACCGGTTCTGTCAT-30, Rv Primer:
50-GGTCATAACCTGGTTCATCATCAC -30; Eurofins Genomics; Les Ulis,
France).
2.9. Hematoxylin-eosin staining and UCP1 immunohistochemistry
Adipose tissue depots were fixed in 10% buffered formaldehyde and
subsequently treated for histological study by dehydration (increasing
alcohol concentrations), mounting in xylene and immersion in paraffin.
The paraffin blocks were sliced into 3 mm sections that were pro-
cessed, deparaffinized in xylene, rehydrated and rinsed in distilled
water and then stained either for hematoxylin-eosin or UCP1 immu-
nohistochemistry. In the hematoxylin-eosin study, slices were first
stained with hematoxylin for 5 min, washed and stained again with
eosin for 1 min. For UCP1 immunohistochemistry, slices were incu-
bated overnight with the primary antibody (UCP1, Abcam; Cambridge,
UK), washed and incubated with the secondary antibody (ENVISION (a
mixture of anti-mouse and anti-rabbit from DAKO; Glostrup,
Denmark)). Images were taken in an optical microscope with a digital
camera Olympus XC50 (Olympus Corporation; Tokyo, Japan) at 40X.
Adipocyte area was quantified using ImageJ 1.33 software (NIH,
Bethesda, MD, USA).
2.10. Statistical analysis
All data are presented as mean  SEM. For statistical analysis, SPSS
was used and statistical significance was determined by Student’s t-
test or 2-way ANOVA in the case of the body weight, food intake and
temperature measurements (Figure 2). P < 0.05 was considered
significant.
3. RESULTS
3.1. Central T3 infusion induces oxygen consumption in mice
To establish the existence of thermogenesis induced by central T3-
infusion, we used mice that were chronically thyroid hormone-
stimulated centrally through minipumps connected to a cannula tar-
geting the lateral ventricle of the brain. To ensure that the mice had
available a sufficiently high BAT thermogenic capacity to make T3-
induced thermogenesis from BAT observable, mice were acclimated
to 18 C for about a month before the experiment [7]. Further, to
ensure that any extra heat contribution from thyroid-hormone-induced
thermogenesis would be observable, the acute analysis of thermo-
genesis was performed at thermoneutrality. As seen in Figure 1A (left,
blue line), as expected, marked circadian alterations in metabolism
were observed in the untreated wildtype mice. In the T3-treated mice
(red line), oxygen consumption (VO2) was clearly elevated. Thus, this is
the first functional confirmation that the increases earlier observed,
e.g. SNS activity in BAT in centrally T3-infused animals [5], are really
associated with increased VO2. Additionally, this constitutes evidence
that the central model for (certain) T3 effects, so far only demonstratedMOLECULAR METABOLISM 5 (2016) 271e282  2016 The Authors. Published by Elsevier GmbH. This is an op
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were also acclimated to 18 C but where the indirect calorimetry
experiments were also performed at 18 C, we failed to observe any
effect of central T3 infusion on VO2 (Supplemental Figure 1, upper
curves).
To accurately define the VO2 specifically induced by central T3 infu-
sion, we subtracted the running means of the vehicle-infused mice
from those of the T3-treated mice (Figure 1B, left, black line). It be-
comes very evident that the increased VO2 was only observed during
the dark phase; this was unexpected. The central T3 infusion system is
continuously active and the increases in sympathetic activity to BAT
reported earlier were observed during the light phase (in rats) [5]. It is
not presently possible to ascribe the strong diurnal effect of the T3-
infusion to interaction with any other circadian events, although
feeding and muscular activity would, of course, be strong candidates.
Also, in the former experiments, when sympathetic activation was
detected, T3 was given as a single bolus [5], but here a chronic
minipump treatment was utilized.
3.2. UCP1 is essential for T3-induced oxygen consumption
To examine the significance of BAT-derived heat production for the T3-
induced VO2, we followed VO2 in mice lacking UCP1. These mice are
devoid of adrenergically induced VO2 in their brown adipocytes [18], as
well as in their brite/beige adipocytes [19,20]. As seen in Figure 1A,
right, these mice also showed marked circadian patterns in their
metabolism in the untreated state. There was, however, no obvious
effect on VO2 of central T3 infusion in these UCP1-ablated mice.
Indeed, when the specific metabolic effect of central T3 infusion was
calculated (Figure 1B, left, red line), the line did not deviate positively
from zero. Formally, the UCP1-dependence of the T3-effect can be
plotted (Figure 1B, right) as the difference between the two curves
(Figure 1B, left). As thus seen from Figure 1B, the entire effect of
central T3 infusion on VO2 is mediated via UCP1, and no alternative
mechanism for increased metabolism is called into action in the
absence of UCP1. This is thus the first demonstration that not only is
BAT involved in the increased energy expenditure induced by central
T3 infusion but that the increase is totally dependent on the presence
of UCP1.
The data above are quantitatively evaluated in Figure 1CeE. Due to the
marked qualitative differences between the light and dark phases
evident from Figure 1AeB, these phases have been separately
analyzed. In the wildtype mice, there was no statistically significant
effect of central T3 infusion during the light phase (Figure 1C, left), but
central T3 infusion significantly increased the VO2 by 22% during the
dark period (an increase of 17% when analyzed for the light and dark
phases together; P¼ 0.03). No significant effects of central T3 infusion
were seen in the UCP1-ablated mice, either during the light phase or
during the dark phase (Figure 1C, right). In Figure 1D, the effect of T3
during the light phase on the wildtype mice in comparison with the
effect in UCP1-ablated mice is shown. Whereas no differences were
observed during the light phase, the entire T3 effect seen in the
wildtype mice depends on the presence of UCP1 (Figure 1E).
Next, we evaluated the effect of central T3 on the RQ of wildtype and
UCP1 KO mice. Our data showed that central T3 promoted a tendency
to increase the RQ that was lost in UCP1 null animals (Supplemental
Figure 2AeE).
3.3. UCP1 is essential for the pyrexia (“fever”) caused by central
T3 infusion
In Figure 2, we display the development of the body temperature
observed in the middle of the light phase during the entire experiment.en access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 273
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higher body temperature in the T3-treated mice by the second day
after the application of the T3-delivering system, and a clear sustained
difference was observed from day 3 and onwards. This increase inFigure 1: Central T3 infusion induces extra oxygen consumption in a UCP1-dependen
and, two days later, transfered to metabolic chambers where their rate of oxygen consump
wildtype (left) and UCP1 KO mice (right) centrally infused with T3 or vehicle. Mean data from
values minus vehicle values; wildtype black line, UCP1 KO red line. Right: The UCP1-depen
Mean metabolic rate represented as the average O2 consumption during the light and dur
with T3. Values were calculated for each mouse by adding the two last days divided by 2 a
the light phase metabolic rate represented as D ¼ T3 values minus vehicle values (left), an
means (A, B) or means  SEM (C, D, E) of 9 (wildtype vehicle) or 10 (all other) mice; **
274 MOLECULAR METABOLISM 5 (2016) 271e282  2016 The Authors. Published by Elsevier GmbH. Tbody temperature induced by central T3 infusion amounts to about
0.7 C (Figure 2B). Most notably, the T3 treatment counteracted the
decrease in body temperature seen over the experimental period. For
the UCP1-ablated mice, there was no consistent increase in bodyt process. Mice were preacclimated to 18 C, implanted with T3-delivering minipumps
tion (VO2) was followed. The first day in the chambers is not shown. A) Two days VO2 in
9 to 10 mice. B) Left: The effect of T3 on metabolic rate (from A) calculated as D ¼ T3
dent T3 effect calculated from B left as DD ¼ Dwildtype values minus DKO values. C)
ing the dark phases in wildtype (left) and UCP1 KO mice (right), centrally treated or not
nd then calculating the average for all mice in each group (n ¼ 9e10). D) T3 effect on
d as the UCP1-dependent T3 effect (right). E) As D but during the dark phase. Data are
P < 0.01 T3-treated vs. vehicle as analyzed by unpaired t-test.
his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: UCP1-dependent effects of central T3 infusion on body temperature, body weight and food intake. The mice depicted in Figure 1 were followed during the entire T3-treatment period. A) Body temperature from day 0 in
wildtype (left) and UCP1 KO mice (right) centrally treated with T3. B) T3 effect on body temperature represented as D ¼ T3 values minus vehicle values (left) and UCP1-dependent T3 effect represented as DD ¼ Dwildtype values e DKO values
(right). C) Body weight gain in wildtype (left) and UCP1 KO mice (right) centrally treated with T3. The initial average body weight of each group was: WT/Veh 30.7  0.4 g, WT/T3 30.1  0.7 g, KO/Veh 27.0  0.9 g and KO/T3 27.3  0.9 g. Note
that the mice were pre-acclimated to 18 C, and at this subthermoneutral temperature, UCP1-ablated mice are not expected to become more obese than wildtype, rather, the reverse. D) Effect of T3 on body weight gain, represented as D ¼ T3
values minus vehicle values (left), and UCP1-dependent T3 effect represented as DD ¼ Dwildtype values minus DKO values (right). E) Daily food intake in wildtype (left) or UCP1 KO mice (right) centrally treated with T3. F) Effect of T3 on daily
food intake, represented as D ¼ T3 values minus vehicle values (left) and UCP1-dependent T3 effect represented as DD ¼ Dwildtype values minus DKO values (right). The time when the mice were inside the metabolic cages is represented by
the light grey rectangle. Data are mean  SEM as in Figure 1; *, ** and (*) P < 0.05, <0.01 and ¼ 0.06 T3-treatment vs. vehicle as analyzed by unpaired t-test at single time points. 2-way ANOVA was also applied to analyze the dependence of
time and treatment. Figure 2A, left: effect of treatment P ¼ 0.000; effect of time: P ¼ 0.001; Figure 2A, right: effect of treatment P ¼ 0.286; effect of time: P ¼ 0.015; Figure 2C, left: effect of treatment P ¼ 0.006; effect of time: P ¼ 0.014;




































Figure 3: UCP1 dependence of the effect of central T3 on hypothalamic neuro-
peptide and pAMPK levels. After the end of the T3-treatment, mice were killed and
hypothalami dissected out. The graphs show hypothalamic protein levels (upper panels)
and representative western blot images (lower panels) of NPY (A), AgRP (B) and
pAMPK (C) in wildtype (left) and UCP1 KO mice (right) centrally treated with T3. Note
that all samples from each genotype were run in parallel in the same gel. Data are
means  SEM for 7 mice. * and **P < 0.05 and 0.01 T3-treatment vs. vehicle. Vehicle
levels were for each genotype set to 100%.
Original articletemperature, and for both treated and untreated animals, the body
temperature decreased over time (Figure 2A, right).
The increase in body temperature observed in the hyperthyroid state
is often interpreted as hyperthermia, i.e. the animal produces more
heat than it can dispose of. The data presented here do not support
the concept that the higher body temperature in the T3-treated mice
is a hyperthermia caused by the increase in heat production, because
this is observed during the light phase when no increase in VO2 is
evident (Figures 1 and 2). The higher body temperature in the T3-
treated mice should therefore be considered as pyrexia (“fever”),
i.e. a defended new body temperature. This conclusion is principally
in agreement with certain earlier studies on hyperthyroid rats indi-
cating that they maintain a defended increase in body temperature
[21,22].
3.4. UCP1 is essential for the effect of central T3 infusion on body
weight and food intake
As seen in Figure 2C, left, the surgery and the implantation of the
infusion system led to a direct decrease in body weight of about 2 g. In
the non-treated wildtype mice, body weight was thereafter maintained
at this level. However, in the T3-treated mice, a statistically significant
transient decrease of about 1 g was seen. This T3-induced body
weight loss was similar to that observed in rats [5,12]. In the UCP1-
ablated mice, the initial body weight after the operation was gener-
ally maintained, and no consistent effect of T3-treatment was observed
(Figure 2C, right). Thus, the extra body weight loss was fully UCP1-
dependent (Figure 2D) and may be associated directly with the
increased metabolism induced during eating time (dark phase)
(Figure 1).
Probably as a consequence of the anesthesia and the ICV surgery,
during the day after the implantation of the infusion system, the mice
did not eat (Figure 2E), explaining the initial loss of body weight
(Figure 2C). In the following days, feeding was restored in the non-
treated wildtype mice (Figure 2E, left) but then the intake gradually
declined. Food intake in T3-treated wildtype mice remained high,
making them hyperphagic relative to non-treated mice. This relative
hyperphagia clearly allowed for the recovery in weight gain observed in
the T3-treated mice from day 3 (Figure 2CeD). There was no effect of
T3 treatment on food intake in the UCP1 KO mice (Figure 2E, right),
implying that the positive effect of T3 on food intake was dependent on
the presence of UCP1 (Figure 2F).
3.5. UCP1 is essential for the central T3 infusion-induced
expression of orexigenic neuropeptides
At the end of the experiment, the mice were killed and their mediobasal
hypothalami examined for the expression of the feeding-promoting
neuropeptides neuropeptide Y (NPY) and agouti-related peptide
(AgRP). No significant changes were found either in the protein levels
of the loading control (b-actin) or in the basal levels of NPY and AgRP
between wildtype and UPC1 KO mice (Supplemental Figure 3AeB). As
previously shown [5,12], and in keeping with its orexigenic effect
(Figure 2EeF), central administration of T3 increased the protein
expression of these neuropeptides in the hypothalamus of wildtype
mice (Figure 3AeB, left). This may be a direct effect of T3 on the
relevant hypothalamic nuclei [12]. However, strikingly, central T3
infusion failed to induce the expression of the neuropeptides in the
UCP1-ablated mice (Figure 3AeB, right) in which, correspondingly, no
increase in food intake was seen (Figure 2EeF). This is an indication
that activation of BAT leads to an increased utilization of stored energy
(Figure 2CeE), signaling to the brain that its energy stores are
diminished.276 MOLECULAR METABOLISM 5 (2016) 271e282  2016 The Authors. Published by Elsevier GmbH. T3.6. Absence of effect of central T3 infusion in UCP1-ablated mice
is not due to impaired AMPK signaling (or defective AMPK response)
The effects of central T3 infusion on BAT are mediated via decreased
phosphorylation of hypothalamic AMPK [5]. To examine the possibilityhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
that the absence of T3 effects in UCP1-ablated mice could be due to an
unsuccessful response, we examined pAMPK levels in the mediobasal
hypothalamus of wildtype and UCP1 KO. However, T3 reduced the
hypothalamic levels of pAMPK in both groups of animals (Figure 3C);
no significant changes were found either in the protein levels of the
loading control (b-actin) or in the basal levels of pAMPK between
wildtype and UPC1 KO mice (Supplemental Figure 3C). Thus, the
central T3 signaling is intact in the UCP1-ablated mice, and the
absence of effects of UCP1 in these mice must be explained at the
peripheral level.
3.7. Central T3 infusion increases BAT UCP1 levels
In rats, the T3-induced hypothalamic AMPK inactivation leads to
increased sympathetic tone in the nerves innervating BAT [5]. As
chronic sympathetic stimulation is the physiological recruitment
mechanism for BAT [7], we examined the effect of chronic T3 infusion
on BAT recruitment state. Wildtype T3-treated mice showed enlarged
interscapular BAT, as estimated by wet weight (Figure 4A); but an
increase in BAT wet weight is not necessarily associated with a
recruitment of tissue and could instead indicate BAT inactivity (due to
lipid accumulation). However, as total protein amount also tended to be
increased in the T3-treated mice (Figure 4B), these data are
compatible with BAT recruitment.
We further measured the level of UCP1 protein in BAT. We found that in
wildtype mice, relative (Figure 4C) and total (Figure 4D) levels of UCP1
protein (per mg protein) were increased after T3-treatment; no sig-
nificant changes were found in the protein levels of the loading control
(a-tubulin) (Supplemental Figure 3D). Of course, in the UCP1-ablated
mice no UCP1 was detected (Figure 4C). Overall, in keeping with our
former observations on mRNA levels in rats [5], these data indicate thatFigure 4: Central T3 infusion recruits brown adipose tissue. At the end of the T3-trea
and B) total protein levels in iBAT in wildtype and UCP1 KO mice centrally treated with T3
Relative UCP1 protein levels per mg of protein (upper panel, left) and representative weste
gel. D) Estimated total UCP1 protein content in iBAT was obtained by multiplying the dat
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thus probably an increase in thermogenic capacity with time.
3.8. Central T3 infusion induces britening of WAT
After the end of the chronic infusion of T3 into the brain, the body
composition was analyzed by MRI before the mice were decapitated.
As seen in Figure 5A, the total amount of fat in the body was modestly
higher in the T3-treated wildtype mice than in the vehicle-treated
group (P ¼ 0.09), probably reflecting the higher food intake. No dif-
ferences were found in the UCP1-ablated mice (Figure 5AeB).
The morphology of the inguinal white adipose (iWAT) depot was
analyzed by hematoxylin-eosin staining. The size of adipocytes was
reduced after central T3 infusion, thus changing the morphology to-
wards a more BAT-like morphology; no differences were found in
UCP1-ablated mice (Figure 5CeE). When the sections were stained for
UCP1, no staining was observed in untreated wildtype mice, but
positive immunoreactivity was seen in wildtype mice treated with T3
(Figure 5D). As expected, no UCP1 immunoreactivity was observed in
UCP1-ablated mice (Figure 5D). We also examined the effect of central
T3 infusion on UCP1 mRNA levels in the inguinal adipose tissue, as
expressed versus the reference gene HPRT. T3-treatment did not alter
the expression of the reference gene (Supplemental Figure 3E), but the
expression of UCP1 was significantly increased (Figure 5F).
4. DISCUSSION
4.1. Central T3 induces oxygen consumption through a UCP1-
dependent circadian mechanism
Thermogenic effects of thyroid hormones have generally been
considered to be peripheral, in that certain (or most) tissues wouldtment, interscapular brown adipose tissue (iBAT) was dissected out. A) BAT wet weight
. Data are means  SEM from n ¼ 9 (WT/Veh group) or n ¼ 10 (all other groups). C)
rn blot images (lower panel). Note that all the samples were run in parallel in the same
a in B with the data in C for each mouse. n ¼ 7 animals per experimental group.
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Figure 5: Central T3 infusion recruits brite adipose tissue. At the end of the T3-treatment, inguinal white adipose tissue (iWAT) was dissected out. A) Total body fat mass
measured by MRI at the endpoint of the experiment, in wildtype and UCP1 KO mice centrally treated with T3. B) Effect of T3 on the total body fat mass, represented as D ¼ T3
values minus vehicle values (left); UCP1-dependent T3 effect represented as DD ¼ Dwildtype values minus DKO values (right). C) Hematoxylin-eosin staining and D) UCP1
immunohistochemistry, showing UCP1 in sections from iWAT depots in wildtype and UCP1 KO mice centrally treated with T3. The histographs are from 4 different mice but
representative for all 39 mice examined (9 in the WT/Veh group and 10 in the other 3 groups). E) Adipocyte area in wildtype and UCP1 KO mice centrally treated with T3. n ¼ 9.
***P < 0.001 vs. WT vehicle. F) Effect on UCP1 mRNA levels in iWAT in wildtype and UCP1 KO mice centrally treated with T3. UCP1 mRNA levels were normalized to HPRT levels,
and the mean level in vehicle-treated wildtype mice set to 100%. n ¼ 9e10. Ct values were WT/Veh: 25.81  0.73 and WT/T3: 23.25  0.51, P < 0.01; undetected in the UCP1
KO. Data are mean  SEM, **P < 0.01, T3-treatment vs. vehicle.
Original articlerespond thermogenically to a thyroid hormone signal, and the meta-
bolism of the total animal would through this be increased [1e3].
Presently, the possibility that (some of) the metabolic effects of thyroid
hormones instead are centrally induced is discussed [5]. In the present
study, we have for the first time demonstrated that T3, solely through a
brain-mediated process, can induce thermogenesis mediated by UCP1
and thus by brown, and perhaps brite/beige adipose tissues. The ef-
fects of centrally administered T3 on body temperature are indepen-
dent of stimulated VO2. The effects on body weight and food intake
(and on orexigenic neuropeptide levels in the brain) are indirect,
peripherally mediated and result from the activation of BAT caused by278 MOLECULAR METABOLISM 5 (2016) 271e282  2016 The Authors. Published by Elsevier GmbH. Tcentral T3. Chronic activation of BAT through central T3 results in
enhanced recruitment of the tissue, and britening/beiging of inguinal
WAT is also observed. Thus, central mediation may explain many if not
all of the metabolic and thermogenic effects of thyroid hormones
(Figure 6).
The metabolic effects of thyroid hormones on BAT are centrally
mediated [2,5]. Specifically, T3 inhibits AMPK in the VMH, promoting
increased expression of UCP1 through activation of the SNS [5].
However, the essentiality of BAT for centrally induced thyroid ther-
mogenesis has not been demonstrated as yet. We observed here that
T3 infusion in wildtype mice significantly enhanced VO2. No effect ofhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 6: Role of UCP1 role in modulating the central effects of T3 on energy balance. In wildtype mice (left), central T3 regulates feeding through agouti-related peptide
(AgRP) and neuroptide Y (NPY) in the arcuate nucleus of the hypothalamus (ARC). In addition, central T3 modulates the thermogenic program in the brown adipose tissue (BAT) and
the britening/beiging (“browning”) of white adipose tissue (WAT); this effect is mediated via inhibition of AMP-activated protein kinase (AMPK) in the ventromedial nucleus of the
hypothalamus (VMH). This leads to increased thermogenesis, energy expenditure and weight loss, despite hyperphagia. In UCP1 KO mice (right), although central T3 inhibits
hypothalamic AMPK, it fails to induce any change in feeding, BAT thermogenesis, energy expenditure and browning of WAT. This data demonstrate that UCP1 is essential for the
central actions of T3 on energy balance. 3V: third ventricle; SNS: sympathetic nervous system.central T3-treatment was found in mice lacking UCP1. This thus
demonstrates the essential role of UCP1 for central T3-induced ther-
mogenesis. However, the enhanced VO2 was only observable during
the night, despite the chronic release of T3 centrally. This must mean
that the heat production is not due to a direct effect of T3 on nerves
controlling sympathetic stimulation of BAT - but rather seems to
facilitate/enhance the innate nightly BAT stimulation that is most likely
associated with feeding. The mechanism for the selective effect during
the dark phase is unknown. Additionally, as illustrated in Supplemental
Figure 1, the effect is not observable in mice studied at normal animal
house temperatures. This is understandable, as any “extra” stimula-
tion of BAT would be compensated by a thermoregulatory decrease in
the stimulation caused by the cold experienced by the mice at this
temperature [23]. Additionally, in keeping with this idea, we have found
that performing the experiment at thermoneutrality (as here) in mice
pre-acclimated to thermoneutrality resulted in no observable T3-
induced thermogenesis (data not shown). This is understandable in
that the BAT in such animals has a low thermogenic capacity, and the
effect would not be measurable. It may be extrapolated that in humans,
who generally live under thermoneutral conditions, there would be no
brown-fat-derived thermogenesis of the type described here. However,
as discussed below, chronic central T3-treatment, a situation thatMOLECULAR METABOLISM 5 (2016) 271e282  2016 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.commimics central hyperthyroidism [5], leads to BAT recruitment, so an
enhanced thermogenic capacity would develop with time, even in
humans at thermoneutrality.
Our observations also demonstrate that no mechanism other than
UCP1 can mediate central T3-induced thermogenesis. Therefore, it can
be concluded that there are no alternative sources of increased
metabolism induced by central T3-treatment, mediated by any
mechanism in any tissue.
4.2. Central T3-induced elevation of body temperature is
independent of UCP1-mediated thermogenesis
In contrast to the clear UCP1-dependence of the effect of T3 on VO2,
an elevation of body temperature caused by central T3-treatment
was visible in wildtype mice during the light phase when no
elevated thermogenesis was evident in T3-treated mice. This is in
itself a direct demonstration that the T3-induced increase in body
temperature is not hyperthermia (as sometimes implied concerning
thyroid hormone-induced increased body temperatures). This means
it is not due to an overproduction of heat that the mice cannot
dispose of. Rather, T3-treatment alters the body temperature “set-
point”, i.e. T3 induces a fever-like state. Although there are several
indications that enhanced body temperature caused by thyroiden access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 279
Original articlehormone is a fever [21,22], the present study is the first to indicate
that it can be directly caused by central thyroid hormone interacting
in the brain. It may also be noted that these data underline the tenet
that body temperature increases cannot be used as a proxy for VO2.
Indeed, the higher body temperatures here are achieved during the
light phase without increased VO2. As they are at thermoneutrality,
the mice likely can adjust their heat loss in order to maintain their
preferred body temperature, e.g. by altering vasoconstriction/dilation
in their tails [24]. Another important question is whether the fever-
like state induced by central T3 is cytokine-mediated. Preliminary
analysis of circulating interleukin-1 (IL-1) and interleukin-6 (IL-6)
showed no changes after ICV T3 (data not shown), which may
suggest that they are not involved in the pyrexic actions of T3. In any
case, these data should be taken with care and further work will be
necessary, for example using IL-1 and IL-6 deficient mice to address
this question.
4.3. Central T3-treatment effects on hypothalamic neuropeptides
are dependent on brown-fat activation
Our observations here indicate that the positive effects of T3-treatment
on food intake earlier observed [5] - and the corresponding increases
in the levels of food-intake-stimulatory peptides in the hypothalamus
[12] - do not occur in mice that lack UCP1. The molecular details of
this mechanism are unclear but one possibility may be that lack of
thermogenic machinery in the UPC1 KO mice would account for less
fuel demands and a lack of necessity for increased feeding. Whatever
the case, these data suggest that UCP1 contributes to the control of
energy balance not only through the regulation of energy expenditure
but also through appetite control by modulating T3 action. An alter-
native might be the existence of humoral feedback mechanisms be-
tween the brain and BAT; for example recent data from our group have
demonstrated that bone morphogenetic protein 8B (BMP8B), a bato-
kine, exerts a deep impact on hypothalamic networks [16]. Changes in
adiposity may also promote alterations in leptin levels that could affect
neuropeptide expression. In this regard, it has been already reported
that the anorexic effect of leptin is reduced in UCP1 KO and that UCP1
enhances the leptin action at the hypothalamus [25]. Further work will
be necessary to address the exact mechanism by which UCP1 defi-
ciency in BAT leads to changes in neuropeptide expression. In this
sense, it is also important to consider that a limitation of our study was
the analysis of neuropeptide expression by using western blot from
mediobasal hypothalamic samples, which does not allow conclude
nuclei-specific regulations. Therefore, an in situ hybridization
approach would be more adequate. Those things said, it is also
important to keep in mind that we observed changes in the expression
of AgRP and NPY. AgRP is specifically expressed in the medial part of
the arcuate nucleus (ARC) [26], suggesting that the protein changes
are specific for that neuronal population. In the case of NPY, it is
expressed in both the ARC and the dorsomedial nucleus of the hy-
pothalamus (DMH), where its levels are constitutively lower. Moreover,
NPY in the DMH has been demonstrated to be highly expressed only in
very specific situations, such as pregnancy and lactation [27e29] as
well as in melanocortin deficiency [30]; thus, it is unlikely that it can
significantly contribute to the protein levels that we detected by
western blot.
4.4. Chronic central T3-stimulation induces BAT recruitment
Chronic adrenergic stimulation of BAT leads to BAT recruitment [7]. As
expected, BAT in T3-treated mice shows clear signs of recruitment,
such as increased total protein in the tissue, increased concentration of
UCP1 in total tissue protein and, most importantly, in the total amount280 MOLECULAR METABOLISM 5 (2016) 271e282  2016 The Authors. Published by Elsevier GmbH. Tof UCP1 in the tissue (the biochemical parameter that most accurately
reflects the total thermogenic capacity of the tissue [7,31]). The
recruitment process induced by T3-treatment indicates that even if
mice (or humans) would be acclimated to thermoneutrality, and thus
possess very little BAT with a very limited thermogenic response to T3-
treatment, central hyperthyroidism would with time lead to substantial
recruitment of BAT and thus to acquiring significant thermogenic
capacity.
4.5. Central T3-induced britening/beiging in inguinal WAT is UCP1
dependent
Also in certain WAT depots, chronic adrenergic stimulation leads to
expression of UCP1 (see [23]). Here, we show for the first time that
central T3 administration also increases UCP1 mRNA in the iWAT. The
signaling pathway for this effect is not self-evident. A suggestion could
be the observations (see [23]) that the brain regions innervating BAT
and WAT are in similar anatomical locations. Thus, it could simply be
that the nerves innervating WAT are activated when the nerves for the
BAT are activated, and the effect of central T3-treatment would
therefore be similar in the two tissues.
4.6. The relationship between central T3-induced thermogenesis
and peripherally T3-induced thermogenesis
The present study is limited to investigating the significance of UCP1
for the actions of centrally infused T3. Although it is likely that this
pathway is important for the general effect of thyroid hormones in the
body, the conclusions from the present study cannot be extrapolated to
explain all the effects of peripheral administration of thyroid hormones.
The central pathway studied here may or may not be the only way T3
can activate thermogenesis. Thus, UCP1-dependent or UCP1-
independent metabolic effects of peripheral thyroid hormone may
exist, only to be revealed through future studies.
We have here studied the results of central administration of T3 on
metabolic rate, body weight and food intake. There are probably more
effects of central T3-induced sympathetic activation [32,33]. To which
degree such effects are also dependent on BAT activation has not been
examined here. However, as central T3-treatment leads to substantial
increases in metabolic rate and in food intake, and as these effects are
totally dependent on BAT activity, it may be that additional effects are
BAT dependent: increased metabolism, food intake and food handling
in the body will clearly affect many other systems in the body (heart
rate, liver metabolism) that may or may not be secondary to the
phenomena described here. Analysis of liver and cardiovascular
function in centrally T3-treated UCP1 KO mice will examine that
possibility.
4.7. Perspectives
The central mechanism (the VMH AMPK-SNS-BAT axis) leading to BAT
activation was initially described for thyroid hormones [5]. However,
there are now data indicating that this pathway is shared by other
agents that are experimentally administered centrally, such as leptin
[34], BMP8B [16], estradiol [10], glucagon like peptide-1 (GLP-1) [35]
and nicotine [17,36]. It is tempting to speculate that the central
thermogenic effect of those factors may also be impaired in UCP1 KO
mice. This hypothesis will require further investigation and will help to
understand the physiological mechanism modulating energy homeo-
stasis. All data investigating these central effects of diverse agents
stimulating and perhaps being mediated through BAT are obtained in
rodents. The present realization that adult humans possess active BAT
[37] evidently implies that similar mechanisms may occur, at least in a
subpopulation of humans.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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